Design and Synthesis of a 18F-Radiolabeled Pyrrolo[2,3-d]pyrimidine Ligand as a CSF1R Receptor PET Imaging Agent

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS
Srinivasulu Cherukupalli, Morten Karlsen, Bård Helge Hoff, Eirik Sundby
{"title":"Design and Synthesis of a 18F-Radiolabeled Pyrrolo[2,3-d]pyrimidine Ligand as a CSF1R Receptor PET Imaging Agent","authors":"Srinivasulu Cherukupalli,&nbsp;Morten Karlsen,&nbsp;Bård Helge Hoff,&nbsp;Eirik Sundby","doi":"10.1002/jlcr.4131","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Colony-stimulating factor 1 receptor (CSF1R or c-FMS), a class III receptor tyrosine kinase, is significantly expressed in mononuclear phagocytes and in the central nervous system. It has been identified as a potential drug and imaging target in numerous inflammatory, cancerous, and neurodegenerative diseases. Despite several attempts, no validated CSF1R PET tracer is currently available. Herein, we report the design and synthesis of a <sup>18</sup>F-radiolabeled pyrrolo[2,3-<i>d</i>]pyrimidine molecule based on previously developed potent and selective CSF1R inhibitors. Initially, a nonlabeled fluorinated compound was synthesized using conventional and microwave methods, and it exhibited potent CSF1R inhibitory activity (IC<sub>50</sub> = 6 nM). A tosylate precursor was then synthesized for subsequent radiofluorination. The <sup>18</sup>F-radiolabeled compound was produced using K[<sup>18</sup>F]F Kryptofix 222 (K<sub>2.2.2</sub>)-carbonate in acetonitrile (10% DMF). The optimal labeling conditions, with a tosylate leaving group at 100°C for 5 min, resulted in the production of the <sup>18</sup>F-radiolabeled pyrrolo[2,3-<i>d</i>]pyrimidine CSF1R inhibitor with high purity and with a molar activity of the final product of 57 GBq/μmol. The synthesized inhibitor might open new possibilities for in vivo imaging in neuroinflammation and related disorders, and future studies will evaluate its performance as a PET tracer.</p>\n </div>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":"68 1-2","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Colony-stimulating factor 1 receptor (CSF1R or c-FMS), a class III receptor tyrosine kinase, is significantly expressed in mononuclear phagocytes and in the central nervous system. It has been identified as a potential drug and imaging target in numerous inflammatory, cancerous, and neurodegenerative diseases. Despite several attempts, no validated CSF1R PET tracer is currently available. Herein, we report the design and synthesis of a 18F-radiolabeled pyrrolo[2,3-d]pyrimidine molecule based on previously developed potent and selective CSF1R inhibitors. Initially, a nonlabeled fluorinated compound was synthesized using conventional and microwave methods, and it exhibited potent CSF1R inhibitory activity (IC50 = 6 nM). A tosylate precursor was then synthesized for subsequent radiofluorination. The 18F-radiolabeled compound was produced using K[18F]F Kryptofix 222 (K2.2.2)-carbonate in acetonitrile (10% DMF). The optimal labeling conditions, with a tosylate leaving group at 100°C for 5 min, resulted in the production of the 18F-radiolabeled pyrrolo[2,3-d]pyrimidine CSF1R inhibitor with high purity and with a molar activity of the final product of 57 GBq/μmol. The synthesized inhibitor might open new possibilities for in vivo imaging in neuroinflammation and related disorders, and future studies will evaluate its performance as a PET tracer.

18f放射性标记吡咯[2,3-d]嘧啶配体作为CSF1R受体PET显像剂的设计与合成
集落刺激因子1受体(CSF1R或c-FMS)是酪氨酸激酶的III类受体,在单核吞噬细胞和中枢神经系统中显著表达。它已被确定为许多炎症、癌症和神经退行性疾病的潜在药物和成像靶点。尽管多次尝试,目前还没有有效的CSF1R PET示踪剂。在此,我们报道了基于先前开发的强效和选择性CSF1R抑制剂的18f放射性标记吡咯[2,3-d]嘧啶分子的设计和合成。首先,采用常规方法和微波方法合成了一种无标记的氟化化合物,该化合物具有较强的CSF1R抑制活性(IC50 = 6 nM)。然后合成一种tosylate前体,用于随后的放射性氟化。用K[18F]F Kryptofix 222 (K2.2.2)-carbonate在乙腈(10% DMF)中制备了18F放射性标记的化合物。在最佳标记条件下,在100°C条件下,tosylate离开基团5 min,可制得高纯度的18f放射性标记吡咯[2,3-d]嘧啶CSF1R抑制剂,最终产物的摩尔活性为57 GBq/μmol。合成的抑制剂可能为神经炎症和相关疾病的体内成像开辟新的可能性,未来的研究将评估其作为PET示踪剂的性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信